Literature DB >> 18829859

Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor.

Tomohiko Usui1, Kenji Sugisaki, Aya Iriyama, Seiichi Yokoo, Satoru Yamagami, Norihiro Nagai, Susumu Ishida, Shiro Amano.   

Abstract

PURPOSE: To determine the role of angiotensin II type 1 receptor (AT1R) signaling in corneal neovascularization.
METHODS: Corneal neovascularization was induced by suturing 10-0 nylon 1 mm away from limbal vessels in C57 BJ6 mice. Angiotensinogen and its receptor (AT1R) gene expression levels were evaluated by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). The expression of angiotensin II (Ang2) and AT1R was confirmed by Western blotting and immunohistochemistry. To investigate the function of Ang2 in corneal neovascularization, infiltrating macrophages in vascularized corneas and the neovascularized area were investigated after intraperitoneal injection of an AT1R antagonist (telmisartan, 10 mg/kg). Further, corneal mRNA of VEGF, MCP-1, IL-6, ICAM-1, and TNF-alpha was examined in control and telmisartan-treated mice.
RESULTS: Ang2 and AT1R markedly increased in the neovascularized corneas compared with normal corneas. Ang2 and AT1R were expressed in epithelium and stromal cells (vascular endothelium, infiltrating leukocytes, and keratocytes) in neovascularized cornea at protein levels and were weakly detected in normal corneal epithelium. Infiltrating macrophages were reduced in telmisartan-treated mice on day 7 after suturing. Neovascularized area in the cornea of telmisartan-treated mice was 70% smaller than that of control mice on day 7 after suturing. A PPAR-gamma antagonist partially, but significantly, reversed the suppressive effect of telmisartan on induction of corneal neovascularization. The expression of VEGF, MCP-1, IL-6, and ICAM-1 was significantly inhibited in telmisartan-treated mice.
CONCLUSIONS: These findings indicate that Ang2, abundantly expressed in neovascularized corneas, has a significant role in inflammation-related driven corneal neovascularization. AT1R may be a therapeutic target for the suppression of corneal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829859     DOI: 10.1167/iovs.07-0964

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Novel bioactivity of NHERF1 in corneal neovascularization.

Authors:  Peng Chen; Ye Wang; Lingling Yang; Changyou Li; Yao Wang; Lixin Xie; Yiqiang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-10       Impact factor: 3.117

Review 2.  LncRNAs in ocular neovascularizations.

Authors:  Yacouba Cissé; Lang Bai; Min-Ting Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 3.  Telmisartan: a review of its use in cardiovascular disease prevention.

Authors:  James E Frampton
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

4.  lncRNA MIAT suppression alleviates corneal angiogenesis through regulating miR-1246/ACE.

Authors:  Yanhui Bai; Weiqun Wang; Youmei Zhang; Fengyan Zhang; Haohao Zhang
Journal:  Cell Cycle       Date:  2019-03-05       Impact factor: 4.534

5.  Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.

Authors:  Peng Chen; Hongmei Yin; Yao Wang; Jing Mi; Wenxiao He; Lixin Xie; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-02-27       Impact factor: 2.367

6.  Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo.

Authors:  Ajay Sharma; Daniel I Bettis; John W Cowden; Rajiv R Mohan
Journal:  Mol Vis       Date:  2010-04-23       Impact factor: 2.367

7.  Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study.

Authors:  Hua Gao; Jingjing Zhang; Ting Liu; Weiyun Shi
Journal:  Mol Vis       Date:  2011-12-24       Impact factor: 2.367

Review 8.  The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.

Authors:  Paulina Escandon; Brenda Vasini; Amy E Whelchel; Sarah E Nicholas; H Greg Matlock; Jian-Xing Ma; Dimitrios Karamichos
Journal:  Exp Eye Res       Date:  2021-05-16       Impact factor: 3.770

Review 9.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

Review 10.  The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).

Authors:  Hongyan Zhou; Wensong Zhang; Miaomiao Bi; Jie Wu
Journal:  Int J Mol Med       Date:  2016-08-04       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.